Literature DB >> 9146340

Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group.

J F Vansteenkiste1, P R De Leyn, G J Deneffe, G Stalpaert, K L Nackaerts, T E Lerut, M G Demedts.   

Abstract

BACKGROUND: The selection of stage IIIA N2 non-small cell lung cancer patients for primary surgical treatment remains controversial.
METHODS: One hundred forty patients with resected non-small cell lung cancer who eventually proved to have pathologic N2 disease were studied with a univariate and multivariate analysis of prognostic factors.
RESULTS: Nineteen patients had a positive mediastinoscopy; the others had a preoperative N0 or N1 stage. Complete resection rate was 80.7%. Five-year survival was 20.8% (95% confidence interval, 17.2% to 24.4%), 32.2% in mediastinoscopy-negative patients. In the univariate analysis, clinical N stage at mediastinoscopy, complete resection, performance status, T stage, number of metastatic levels in adenocarcinoma, and nodal capsule rupture were important factors. In a multivariate model, survival was worse in case of higher T stage (relative risk = 1.43), lower performance status (relative risk = 1.37), involvement of more than one node level (relative risk = 1.68), nonsquamous histology (relative risk = 1.29) and clinical N2 stage (relative risk = 1.43). Long-term survival was unlikely when lactic dehydrogenase or carcinoembryonic antigen levels were elevated.
CONCLUSIONS: In clinical N0 or N1 cancer, complete resection resulted in reasonable survival prospects. In patients with N2 disease discovered at mediastinoscopy, surgical treatment was only worthwhile in case of minimal N2. Several unfavorable prognostic factors could be identified in the univariate analysis and confirmed in a multivariate Cox model.

Entities:  

Mesh:

Year:  1997        PMID: 9146340     DOI: 10.1016/s0003-4975(97)00314-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  28 in total

Review 1.  Positron emission tomography (PET) in the evaluation of patients with cancer.

Authors:  H A Godwin; J H Zuger
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

2.  Prognostic significance of persistent mediastinal metastasis following induction therapy in large (> or = 2 cm) N2 or N3 non-small cell lung cancer.

Authors:  Noriyoshi Sawabata; Mitsunori Ohta; Hajime Maeda; Shin-ichi Takeda; Hiroshi Hirano; Yoshitomo Okumura; Hiroki Asada
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-04

3.  Mediastinal lymphatic drainage from pulmonary lobe based on CT observations of histoplasmosis: implications for minimal N2 disease of non-small-cell lung cancer.

Authors:  Koji Takahashi; William Stanford; Edwin Van Beek; Brad Thompson; Brian Mullan; Yutaka Sato
Journal:  Radiat Med       Date:  2007-10-26

4.  Which subgroup of patients with pathologic N2 non-small cell lung cancer benefit from surgery?

Authors:  Yasunobu Funakoshi; Yukiyasu Takeuchi; Hidenori Kusumoto; Toru Kimura; Hajime Maeda
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-25       Impact factor: 4.553

5.  Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer.

Authors:  K Ichiki; N Mitani; Y Doki; H Hara; T Misaki; I Saiki
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.

Authors:  Chi-Fu Jeffrey Yang; Syed M Adil; Kevin L Anderson; Robert Ryan Meyerhoff; Ryan S Turley; Matthew G Hartwig; David H Harpole; Betty C Tong; Mark W Onaitis; Thomas A D'Amico; Mark F Berry
Journal:  Eur J Cardiothorac Surg       Date:  2015-12-30       Impact factor: 4.191

7.  Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.

Authors:  Paolo Borghetti; Fernando Barbera; Marco Lorenzo Bonù; Francesca Trevisan; Stefano Ciccarelli; Paola Vitali; Marta Maddalo; Luca Triggiani; Nadia Pasinetti; Sara Pedretti; Bartolomea Bonetti; Gianluca Pariscenti; Andrea Tironi; Alberto Caprioli; Michela Buglione; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2016-05-26       Impact factor: 3.469

Review 8.  Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis.

Authors:  Claudio Luchini; Nicola Veronese; Alessia Nottegar; Monica Cheng; Takuma Kaneko; Camilla Pilati; Fabrizio Tabbò; Brendon Stubbs; Antonio Pea; Fabio Bagante; Jacopo Demurtas; Matteo Fassan; Maurizio Infante; Liang Cheng; Aldo Scarpa
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

Review 9.  Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer.

Authors:  Henk Kramer; Harry J M Groen
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

10.  Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.

Authors:  Luigi Moretti; David S Yu; Heidi Chen; David P Carbone; David H Johnson; Vicki L Keedy; Joe B Putnam; Alan B Sandler; Yu Shyr; Bo Lu
Journal:  Oncologist       Date:  2009-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.